The National Partner Society Abstract Achievement Awards consist of a $2,000 grant awarded to an international hematologist, who must be a member of the supporting organization and resident of the respective country, to help advance knowledge and inspire continued professional development in hematology. The awardees can be undergraduate students, medical students, graduate students, resident physicians, or postdoctoral MD or PhD fellows. The first set of awardees were announced in October 2019.

ASH-Haematology Society of Australia and New Zealand (HSANZ) Abstract Achievement Awards

The ASH-HSANZ AAA is granted to up to two trainees who are first or senior author and presenter of the most meritorious country-specific project.

Chong Chyn Chua, MBBS, FRACP, FRCPA
The Alfred Hospital and Monash University
Abstract 462
Title: Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study
617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel Treatment and Analytical Approaches to Heterogenous AML
Sunday, December 8, 2019, 1:15 p.m., Valencia BC (W415BC), Level 4 (Orange County Convention Center – map it)

ASH-Japanese Society of Hematology (JSH) Abstract Achievement Awards

The ASH-JSH AAA is granted to up to three trainees who are the first or senior author and presenter of the most meritorious country specific project.

Takeshi Fujino, MD
The University of Tokyo
Abstract 821
Title: Mutant ASXL1 Promotes Expansion of the Phenotypic Hematopoietic Stem Cell Compartment
503. Clonal Hematopoiesis: Aging and Inflammation
Monday, December 9, 2019, 5:30 p.m., W314, Level 3 (Orange County Convention Center – map it)

Haruko Shima, MD, PhD
Keio University School of Medicine
Abstract 25
Title: Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study)
632. Chronic Myeloid Leukemia: Therapy: Predictors of TKI Discontinuation and TFR Outcomes
Saturday, December 7, 2019, 7:30 a.m., Valencia D (W415D), Level 4 (Orange County Convention Center – map it)

Koya Ono, MD
Tohoku University Graduate School of Medicine
Abstract 3530
Title: Molecular Characterization and Novel Therapeutic Strategy for X-Linked Sideroblastic Anemia
102. Regulation of Iron Metabolism: Poster III
Monday, December 9, 2019, 6:00 p.m.-8:00 p.m., Hall B, Level 2 (Orange County Convention Center – map it)

ASH-Society Italiana di Ematologia (SIE) Abstract Achievement Awards

The ASH-SIE AAA is granted to up to two trainees who are the first or senior author and presenter of the most meritorious country specific project.

Chiara Magnani, PhD
University of Milano-Bicocca/Fondazione MBBM
Abstract 200
Title: Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)
704. Immunotherapies I
Saturday, December 7, 2019, 12:15 p.m., Valencia A (W415A), Level 4 (Orange County Convention Center – map it)

Pier Edoardo Rovatti, MD
IRCCS San Raffaele Scientific Institute
Abstract 513
Title: Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses
723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Disease Monitoring and Management of Post-HCT Relapse
Sunday, December 8, 2019: 5:00 p.m., Sunburst Room (W340) (Orange County Convention Center – map it)

ASH-British Society of Hematology (BSH) Abstract Achievement Award

The ASH-BSH AAA is granted to up to three trainees who are the first or senior author and presenter of the most meritorious submitted abstract.

Samah Alimam, FRCPath
King’s College
Abstract 308
Title: Molecular, Epigenetic and Gene Expression Profiling of Triple Negative Essential Thrombocythaemia
635. Myeloproliferative Syndromes: Basic Science: Pathophysiology of Myeloproliferative Neoplasms
Saturday, December 7, 2019, 4:15 p.m., Valencia BC (W415BC), Level 4 (Orange County Convention Center – map it)

Claire Burney, MBBS
University Hospitals Bristol
Abstract 701
Title: Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 – a Retrospective Study from the LWP-EBMT
723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Outcomes and Late Effects
Monday, December 9, 2019, 11:30 a.m., W304EFGH, Level 3 (Orange County Convention Center – map it)

Konstantinos Tzelepis, PhD
University of Cambridge
Abstract 403
Title: Pharmacological Inhibition of the RNA m6a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia
802. Chemical Biology and Experimental Therapeutics: Novel Compounds and Mechanisms of Action
Sunday, December 8, 2019, 9:30 a.m., W414AB, Level 4 (Orange County Convention Center – map it)

 

Learn More

To learn more about these new partner awards, and to apply for the future award cycle, visit www.hematology.org/awards/abstract-achievement.

 

Share This